Drugs / URO-902
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04211831 | Dec 2019 → Nov 2021 | overactive bladder | Urovant Sciences GmbH | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | URO-902 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04211831 ↗ |
| Route | Other | “intradetrusor injection” NCT04211831 ↗ |